All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Extended prophylaxis of venous thromboembolism with idraparinux

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F07%3A00003945" target="_blank" >RIV/00216208:11150/07:00003945 - isvavai.cz</a>

  • Result on the web

  • DOI - Digital Object Identifier

Alternative languages

  • Result language

    angličtina

  • Original language name

    Extended prophylaxis of venous thromboembolism with idraparinux

  • Original language description

    We evaluated the efficacy and safety of a 6-month extension of prophylaxis against recurrent venous thromboembolism with idraparinux in patients who had initially received 6 months of prophylaxis with an anticoagulant. Methods: We randomly assigned patients who had completed 6 months of prophylaxis with idraparinux or a vitamin K antagonist and in whom extended anticoagulation was warranted to receive once-weekly injections of 2.5 mg of idraparinux or placebo for 6 months without monitoring. Conclusions: During a 6-month extension of thromboprophylaxis, idraparinux was effective in preventing recurrent thromboembolism but was associated with an increased risk of a major hemorrhage.

  • Czech name

    Prodloužená profylaxe žilního tromboembolismu s idraparinuxem

  • Czech description

    Zkoumali jsme účinnost a bezpečnost 6 měsíčního prodloužení profylaxe proti rekurentnímu venóznímu tromboembolizmu idraparinuxem u pacientů, kteří dostávali 6 měsíců antikoagulační profylaxi. Metody: pacientům po 6 měsíční profylaxi idraparinuxem nebo antagonistou vitamínu K, u kterých byla antikoagulační léčba vhodná, byly náhodně podávány týdenní i.v. 2,5 mg idraparinux nebo placebo 6 měsíců bez monitorování. Závěry: idraparinux byl účinný při prevenci tromboembolizmu, ale zvyšoval riziko významného krvácení.

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FD - Oncology and haematology

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    S - Specificky vyzkum na vysokych skolach

Others

  • Publication year

    2007

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    New England Journal of Medicine

  • ISSN

    0028-4793

  • e-ISSN

  • Volume of the periodical

    357

  • Issue of the periodical within the volume

    11

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    8

  • Pages from-to

    1105-1112

  • UT code for WoS article

  • EID of the result in the Scopus database